Getting to market faster clearly has benefits, but there are also potential downsides for drug companies, too. You need to know the options and consider the wider implications. The options for faster market access multiplied in the last three years, with new opportunities available both before and after regulatory approval, as well as new ways to speed up the reimbursement process. Deciding the right way forward is more complex than ever before.
This report covers all the options but has focused on talking with the experts who have really achieved faster access and finding out their views on the newest initiatives such as the U.K.’s Early Access to Medicines Scheme (EAMS). It offers a powerful combination of extensive independently researched data plus “lived experience” from seven experts who have already gone through the process. Be guided on the following:
- The latest thinking: Are you fully aware of all of the new opportunities to speed up market access in Europe and the U.S.? Whether you’re considering one or multiple territories, get up-to-speed on all your options and find out how you could take advantage.
- Evaluating various routes: What are the strategic pros and cons for gaining early access before regulatory approval, expediting the regulatory approval process, or speeding up reimbursement? Which option (or options) will best suit your drug and market?
- Taking a balanced viewpoint: Take a step back and gain a better understanding of the potential negatives further down the line. What possible downsides or unforeseen consequences must you also consider? What should your exit plan be?
- Cover all bases: Tackle silo thinking with one comprehensive report that gives the full picture from all perspectives whether your team is focused on compassionate use, regulatory approval, or market access.